new version V2017

Canagliflozin antidiabetic drugs
Description Results

Invokana      

  • Group by...

pdf
TrialStudied treatmentControl treatmentpatientsROBResultNCT

diabetes type 2

CANVAS, 2017canagliflozinplacebo Exploratory Conclusive NCT01032629
3005: monotherapy ongoing canagliflozinplacebo -
CANTATA-D ongoing canagliflozinplacebo (add-on MET) - NCT01106677
3009: Add-on to MET ongoing canagliflozinplacebo (add-on MET) -
3008: Add-on to insulin ongoing canagliflozinplacebo (add-on MET) -
3015: Add-on to MET + SU ongoing canagliflozinplacebo (add-on MET+SU) -
3002: Add-on to MET + SU ongoing canagliflozinplacebo (add-on MET+SU) -
3012: Add-on to MET +TZD ongoing canagliflozinplacebo (add-on MET+TZD) -
3008: Add-on to SU ongoing canagliflozinplacebo (add-on SU) -



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons